AstraZeneca, Ionis drug fails big heart disease study in major setback

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...
Hosted on MSN

AstraZeneca’s New Phase I Study on AZD5492: What Investors Need to Know

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Easily unpack a company's performance with ...
Zacks Investment Research on MSN

AstraZeneca's stock drops on Wainua's setback in ATTR-CM study

Shares of AstraZeneca AZN fell nearly 8% in pre-market trading today after the company announced the failure of a phase III ...
U.S. News & World Report

AstraZeneca Therapy for Clearing Protein Deposits Fails Main Goal in Late-Stage Study

(Reuters) -AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the body, ...
Nasdaq

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca AZN reported overall survival (OS) data from a late-stage study, which evaluated its partner Daiichi Sankyo’s investigational candidate, datopotamab deruxtecan (Dato-DXd), compared with ...
Nasdaq

Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals

Ionis Pharmaceuticals IONS announced positive top-line data from the phase III NEURO-TTRansform study on its investigational anti-sense drug eplontersen in patients with hereditary ...
The Globe and Mail

AstraZeneca’s Opemalirsen Renal Study Completion: What Investors Should Watch Next

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' ...